Consultancy: Akebia, AstraZeneca, Fresenius Medical Care, and Novo Nordisk Grant/research support: Fresenius Medical Care* Speaker bureaus: AstraZeneca and Novo Nordisk *Monies paid to institution. Mark J. Sarnak, MD, MS, is chief of the Division of Nephrology at Tufts Medical Center and the Gerald J. and Dorothy R. Friedman Professor of Medicine at Tufts University School of Medicine, Boston, MA, USA. Dr. Sarnak s primary research interest is in cardiovascular disease in CKD. He has also focused on cognitive function, novel biomarkers, and hyper- tension in CKD. Dr. Sarnak s research is funded by the NIH. www.kidney-international.org biographic and disclosure information He is a previous recipient of the Shaul Massry Award from the US National Kidney Foundation. Dr. Sarnak has a long record of national and international leadership positions in nephrology. He was Co-Chair and lead author of a review commissioned by the Kidney Council of the American Heart Association, CKD as a Risk Factor for Cardiovascular Disease. He chaired the subgroup covering CKD patients without diabetes on the previous KDIGO Blood Pressure Guideline. He chaired the Kidney Disease Outcomes Quality Initiative Commentary on the KDIGO Clinical Practice Guideline for Lipid Management in CKD, and most recently, he co-chaired the KDIGO Controversies Conference on Coronary Artery and Valvular Disease in CKD. Dr. Sarnak is a previous recipient of a K24 Midcareer Career Award in Patient-Oriented Research and has men- tored more than 20 research fellows and 9 junior faculty members. He has published more than 350 articles, including more than 85 peer-reviewed, non-review articles, with his mentee as the rst author. His mentees now include professors of medicine and chiefs of divisions of nephrology at other institutions. Consultancy: Akebia*, Bayer, and Cardurion Pharmaceuticals Grant/research support: National Institutes of Health* *Monies paid to institution. 